KCT0008451尚未招募Unknown
ovel Combinations for Orphan Myeloma: The NORM Platform Study
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Previous bortezomib therapy and either
- •Failure to achieve at least a partial response during treatment or within 6 months of discontinuing treatment with bortezomib OR
- •Progressive disease during treatment or within 6 months of discontinuing treatment with bortezomib OR
- •Contraindication or experienced an intolerance to treatment with bortezomib
- •2.Previous lenalidomide therapy and either
- •Treatment failure with lenalidomide, as confirmed by progressive disease during treatment within 6 months of discontinuing lenalidomide
- •A contraindication or intolerance to treatment with lenalidomide
排除标准
- •1.Previous treatment with pomalidomide or selinexor
- •2.Contraindication to pomalidomide, selinexor or dexamethasone
- •3.Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of trial treatment.
- •4.Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia
- •(palliative care).
研究者
相似试验
招募中
2 期
ALLG MM26/D1: Novel Combinations for Orphan Myeloma: The NORM Platform study: Treatment Specific Appendix - Selinexor, Pomalidomide, Dexamethasone (SPd)Relapsed/ Refractory Multiple MyelomaCancer - MyelomaACTRN12622001313729Australasian Leukaemia & Lymphoma Group140
进行中（未招募）
不适用
Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III studyMultiple MyelomaEUCTR2005-003770-23-ATF. Hoffmann-La Roche Ltd424
招募中
不适用
ALLG MM26/NORM: Novel Combinations for Orphan Myeloma: The NORM platform study Master Protocolrelapsed/refractory multiple myelomaCancer - MyelomaACTRN12622001308785Australasian Leukaemia & Lymphoma Group70
进行中（未招募）
不适用
Randomised comparisons, in myeloma patients of all ages, of thalidomide, lenalidomide, carfilzomib and bortezomib induction combinations, and of lenalidomide and combination lenalidomide vorinostat as maintenance - Myeloma XIewly diagnosed patients with symptomatic myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2009-010956-93-GBniversity of Leeds4,000
已完成
不适用
Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General HospitalBlood - Haematological diseasesMultiple MyelomaACTRN12612000024842Clifford Craig Medical Trust Fund10